11119 North Torrey Pines Road
147 articles with Viking Therapeutics
12/20/2017When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.
The gross proceeds to Viking from this offering are approximately $14.8M, before deducting underwriting discounts and commissions and other estimated offering expenses.
Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $12.8M.
All of the shares to be sold in the offering are to be sold by Viking.
Viking Therapeutics Announces Positive Top-Line Results From Phase II Study of VK5211 in Patients Recovering From Hip Fracture
Top-line data showed that the trial achieved its primary endpoint, demonstrating statistically significant, dose dependent increases in lean body mass, less head, following treatment with VK5211 as compared to placebo.
Research and development expenses for the three months ended September 30, 2017 were $3.5 million compared to $2.1 million for the same period in 2016.
Brian Lian, Ph.D., Viking's president and CEO, and Michael Morneau, Viking's CFO, will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, November 8, 2017.
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed NASH at the Annual Meeting of the AASLD
Viking today announced positive final results from an eight-week study of VK2809 in an in vivo model of NASH.
Viking Therapeutics Presents Results From Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association
Viking today announced positive results from a 25-week proof-of-concept study of VK0214 in an in vivo model of X-linked adrenoleukodystrophy (X-ALD).
Viking Therapeutics Announces Top-Line Results From Proof-Of-Concept Study Of VK0214 In In Vivo Model Of X-Linked Adrenoleukodystrophy (X-Ald)
Viking Therapeutics Announces Purchase Agreements For Up To $16.25 Million With Lincoln Park Capital
Viking Therapeutics To Host Key Opinion Leader Event To Discuss Musculoskeletal Therapeutics In Hip Fracture And Other Settings
Viking Therapeutics Announces Results Of Gene Expression Analysis From In Vivo Study Of VK2809 In Non-Alcoholic Steatohepatitis (NASH)
Viking Therapeutics Announces Presentation Of Data From In Vivo Proof-Of-Concept Study Of VK2809 In Glycogen Storage Disease Ia (GSD Ia) At The 13th International Congress Of Inborn Errors Of Metabolism (ICIEM)
Viking Therapeutics To Report Financial Results For Second Quarter 2017 After Market Close On August 9, 2017
Viking Therapeutics Completes Enrollment In Phase II Study Of VK5211 In Patients Recovering From Hip Fracture
Viking Therapeutics Announces Promising Top Line Results From In Vivo Study Of VK2809 In Non-Alcoholic Steatohepatitis (NASH)